Santa Fe Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Santa Fe Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-13,930	Closed	-$1.46M	–	45
2015 Q4	$1.46M	Buy	+13,930	New	+$1.45M	0.24%	169
2015 Q2	–	Sell	-32,594	Closed	-$4.06M	–	486
2015 Q1	$4.06M	Sell	32,594 -11,988	-27%	-$1.27M	0.49%	37
2014 Q4	$4.03M	Sell	44,582 -4	-0%	-$333	0.51%	10
2014 Q3	$3.22M	Buy	44,586 +21,133	+90%	+$1.39M	0.5%	32
2014 Q2	$1.46M	Buy	+23,453	New	+$1.42M	0.22%	198
2014 Q1	–	Sell	-34,429	Closed	-$2.42M	–	472
2013 Q4	$2.42M	Sell	34,429 -1,729	-5%	-$117K	0.4%	85
2013 Q3	$2.61M	Buy	36,158 +25,578	+242%	+$1.7M	0.5%	44
2013 Q2	$590K	Buy	+10,580	New	+$659K	0.12%	293

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Santa Fe Partners's BMRN Position: Q1 2016 in Review

Santa Fe Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2016, closing a stake of 13,930 shares — an estimated $1.46M sold.

Santa Fe Partners first reported a position in BMRN in Q2 2013 and held it in 8 quarters. The position peaked at $4.06M in Q1 2015. 390 funds tracked by Wall St. Rank hold BMRN as of Q1 2016.

Santa Fe Partners reported no remaining BioMarin Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Santa Fe Partners sold 13,930 BioMarin Pharmaceuticals shares in Q1 2016, an estimated $1.46M.
Santa Fe Partners first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 8 quarters.
Santa Fe Partners's BioMarin Pharmaceuticals position peaked at $4.06M in Q1 2015.
390 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2016.

Based on Santa Fe Partners's 13F filing for Q1 2016.